Mylan's Nebivolol NDA User Fee Date Extended To May 31
Three-month delay means the beta blocker's user fee deadline will no longer coincide with the Feb. 28 "walk-away" date for Mylan's acquisition of King. Extension stems from recent submission "of an additional presentation of already submitted data from the nebivolol NDA," Mylan says.
More from Archive
More from Pink Sheet
Japan's trade ministry is providing new support to build domestic capacity for new modalities including cell and gene therapies, as part of wider efforts to support the national bioventure ecosystem.
Coverage data from the two programs suggest Medicare beneficiaries may be more disappointed than Medicaid enrollees by the Trump Administration’s decision not to mandate the programs cover obesity drugs.
The new telework policy returns to the pre-COVID-19 pandemic standard, but still requires reviewers to be at White Oak for sponsor meetings and divisions to have an in-office presence every day.